JOHN P. MCKEARN, Ph.D.
Chief Executive Officer and President
Dr. McKearn is also on the boards of Allakos, OncoResponse, Good Therapeutics, Arch Oncology and Adarza Biosystems. He previously served on the boards of IDM Pharma (acquired by Takeda), Epimmune, Kalypsys, Keel Pharmaceuticals, Lumena Pharmaceuticals (acquired by Shire), Otonomy and ZS Pharma (acquired by Astra Zeneca). Dr. McKearn has co-authored more than 70 published, peer-reviewed scientific papers, and holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease.
Dr. McKearn holds a Ph.D. in Immunology from the University of Chicago and a Bachelor of Science in Biology from Northern Illinois University.
MATTHEW COOPER, Ph.D.
Founder and Chief Scientific Officer
Dr. Cooper holds a Ph.D. in Cancer Genetics from the University of Surrey, Guildford, UK.
KENNETH CHROBAK, Ph.D.
VICE PRESIDENT, PRODUCT DEVELOPMENT
Dr. Chrobak received his Ph.D. in biomedical engineering from Boston University and his Bachelor of Science in chemical engineering from the University of Illinois at Urbana-Champaign.
KAREN GHEESLING MULLIS, Ph.D.
Vice President, Corporate Development
Dr. Gheesling Mullis completed her Ph.D. in Biochemistry at University of Alabama, Birmingham and holds a B.S in Chemistry from Emory University.
MARY CELINE SCOTT, Ph.D., MBA
Vice President, Regulatory Affairs
Dr. Scott received a Ph.D. from Purdue University in Pharmacology (specialization neuroscience), followed by a postdoctoral fellowship at the Mayo Clinic in the emerging field of pharmacogenetics. She also holds an MBA in Pharmaceutical/Chemical Studies from Fairleigh-Dickinson University, an MS in Biology from California State University, Long Beach and a BS in Biological Sciences from the University of California, Irvine.
AYMAN KABAKIBI, Ph.D.
Vice President, Research and development
Dr. Kabakibi received his Ph.D. in biochemistry from the University of Massachusetts Lowell and his Master of Science in medical laboratory sciences from Northeastern University.
MARK LEWIS, Ph.D.
Vice President, finance and business operations
Dr. Lewis has over five years of oncology research experience. Prior to joining Wugen, Dr. Lewis served as a Venture Capital Fellow at BioGenerator, an evergreen investor that creates, grows and funds innovative companies and talented entrepreneurs in the St. Louis region. Dr. Lewis also served as a Research Associate at the Monsanto Company, a global agriculture company specializing in products and tools that help farmers grow crops more efficiently.
Dr. Lewis received his Ph.D. in molecular biology and Master of Art in biology from Washington University in Saint Louis and his Bachelor of Science in biochemistry from Eastern Connecticut State University.